Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study

Journal:
The Lancet Global Health
Published:
DOI:
10.1016/s2214-109x(25)00330-4
Affiliations:
8
Authors:
23
Go to article
Institutions Authors Share
PATH Center for Vaccine Innovation and Access, United States of America (USA)
6.000000
 0.26
EuBiologics Co., Ltd., South Korea
5.000000
 0.22
Institute for Health Research, Epidemiological Surveillance and Training (IRESSEF), Senegal
4.000000
 0.17
Pasteur Institute of Dakar, Senegal
3.000000
 0.13
US Army Medical Research Directorate-Kenya (USAMRU-Kenya), Kenya
1.500000
 0.07
Henry M. Jackson Foundation Medical Research International (HJF) - Kenya, Kenya
1.500000
 0.07
PATH Switzerland, Switzerland
1.000000
 0.04
PATH Kenya, Kenya
1.000000
 0.04
Interested in Medical Microbiology?